Evotec and Bayer partner to develop new treatments to fight kidney diseases
Evotec AG announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute no ... more
FDA approves new five-year-contraceptive of Bayer
The U.S. Food and Drug Administration (FDA) has approved Bayer AG’s new low dose levonorgestrel-releasing intrauterine system (LNG-IUS) which will be marketed in the US under the brand name Kyleena™. Kyleena releases the lowest daily dose of the hormone levonorgestrel in an intrauterine sys ... more
Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer
Evotec AG announced that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
This milestone was achieved under the strategic allia ... more